Newron Pharmaceuticals SpA (NWRN) Stock Statistics & Valuation Metrics

Newron Pharmaceuticals SpA has a market cap or net worth of CHF172.88M. The enterprise value is CHF273.34.

Newron Pharmaceuticals SpA has 21,238,867 shares outstanding. The number of shares has decreased by -2.65% in one year.

Newron Pharmaceuticals SpA’s return on equity (ROE) is 1.19 and return on invested capital (ROIC) is -17.02%.

The current PE Ratio of Newron Pharmaceuticals SpA is ―. Newron Pharmaceuticals SpA’s PEG ratio is 0.21.

In the last 12 months, Newron Pharmaceuticals SpA had revenue of 19.13M and earned -13.24M in profits. Earnings per share was -0.67.

In the last 12 months, operating cash flow was -12.04M and capital expenditures -36.63K, giving a free cash flow of -12.07M billion.

Newron Pharmaceuticals SpA pays an annual dividend of ―, resulting in a dividend yield of ―

Newron Pharmaceuticals SpA upcoming earnings date is Mar 16, 2027, TBA (Confirmed).

Newron Pharmaceuticals SpA as a current ratio of 0.76, with Debt / Equity ratio of -334.18%

In the past 12 months, Newron Pharmaceuticals SpA has paid 885.00K in taxes.

Newron Pharmaceuticals SpA EV to EBITDA ratio is -117.96, with an EV/FCF ratio of 16.52.

Newron Pharmaceuticals SpA has CHF32.99M in cash and marketable securities with CHF39.16M in debt, giving a net cash position of -CHF6.17M billion.

Gross margin is 100.03%, with operating margin of -24.56%, and net profit margin of -69.22%.

The average price target for Newron Pharmaceuticals SpA is CHF44.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy